Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1400459
Main Authors Zhang, Chaoyue, Lin, Yangtao, Kuang, Qianjin, Li, Hongjin, Jiang, Qilong, Yang, Xiaojun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.05.2024
Subjects
Adult
case report
Drug Therapy, Combination
efgartigimod
Female
highly active
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
myasthenia gravis
Myasthenia Gravis - diagnosis
Myasthenia Gravis - drug therapy
refractory
telitacicept
Treatment Outcome
myasthenia gravis
refractory
case report
highly active
efgartigimod
telitacicept
Online AccessGet full text

Cover

More Information
Summary:There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1400459